CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER-4 | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER-4
US Patents

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

Contact Supplier

Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

Contact Supplier

jdmfs-not-supported-m-2025-06-23

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER-4

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

27 API Suppliers, 12 USDMF, 1 CEP/COS, 8 NDC API, 12 Listed Suppliers, $ API Reference Price

27 API Suppliers
12 USDMF
1 CEP/COS
8 NDC API
12 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

103 FDF Dossiers, 73 FDA Orange Book, 15 Europe, 13 Canada, 2 Listed Dossiers

103 FDF Dossiers
73 FDA Orange Book
15 Europe
13 Canada
2 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;INTRAVENOUS - 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML), SOLUTION;INTRAVENOUS - 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML), SOLUTION;INTRAVENOUS - 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)

SOLUTION;INTRAVENOUS - 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)
SOLUTION;INTRAVENOUS - 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)
SOLUTION;INTRAVENOUS - 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Evonik, 7 Rochem International Inc, 19 SPI Pharma, 6 DKSH, 8 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 3 Pfanstiehl, 1 ACG Worldwide, 15 Actylis, 1 Aeon Procare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 1 Avesta Pharma, 28 BASF, 1 Bioplus Life Sciences, 2 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 3 Finar, 9 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 32 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 17 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 3 Pharmatrans-Sanaq, 10 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 39 Roquette, 8 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 1 Symrise, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

94 Fillers, Diluents & Binders, 50 Coating Systems & Additives, 32 Thickeners and Stabilizers, 31 Disintegrants & Superdisintegrants, 31 Direct Compression, 30 Topical, 30 Taste Masking, 29 Controlled & Modified Release, 28 Parenteral, 26 Granulation, 22 Co-Processed Excipients, 22 Solubilizers, 20 Lubricants & Glidants, 19 Chewable & Orodispersible Aids, 19 Film Formers & Plasticizers, 8 Emulsifying Agents, 6 Rheology Modifiers, 6 API Stability Enhancers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents, 3 Surfactant & Foaming Agents, 1 Soft Gelatin

94 Fillers, Diluents & Binders
50 Coating Systems & Additives
32 Thickeners and Stabilizers
31 Disintegrants & Superdisintegrants
31 Direct Compression
30 Topical
30 Taste Masking
29 Controlled & Modified Release
28 Parenteral
26 Granulation
22 Co-Processed Excipients
22 Solubilizers
20 Lubricants & Glidants
19 Chewable & Orodispersible Aids
19 Film Formers & Plasticizers
8 Emulsifying Agents
6 Rheology Modifiers
6 API Stability Enhancers
5 Empty Capsules
4 Vegetarian Capsules
4 Coloring Agents
3 Surfactant & Foaming Agents
1 Soft Gelatin

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 12 News #PharmaBuzz

2 Data Compilation #PharmaFlow
12 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 15 Regulatory FDF Prices

1 US Medicaid Prescriptions
15 Regulatory FDF Prices

MARKET PLACE

5 APIs

5 APIs

PATENTS & EXCLUSIVITIES

1 US Patents

1 US Patents

$ API Ref.Price (USD/KG) : 51 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

5 All

01 1CMP DEV LLC

02 4FRESENIUS KABI USA

filter Patent Number Reset all filters

5 All

01 110632150

02 211813291

03 211925661

API Patent Reset all filters

5 All

01 5Blank

filter FDF Patent Reset all filters

5 All

01 5Y

filter Expiration Date Reset all filters

5 All

01 12039-04-19

02 42041-10-12

Product Main Page

01

CMP DEV LLC

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

The Aesthetic Show

Not Confirmed

CMP DEV LLC

The Aesthetic Show

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2039-04-19

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

US Patent Number : 10632150

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212121

Patent Use Code : U-2789

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-04-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

FRESENIUS KABI USA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

The Aesthetic Show

Not Confirmed

FRESENIUS KABI USA

The Aesthetic Show

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2041-10-12

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

US Patent Number : 11925661

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212832

Patent Use Code : U-4185

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2041-10-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

FRESENIUS KABI USA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

The Aesthetic Show

Not Confirmed

FRESENIUS KABI USA

The Aesthetic Show

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2041-10-12

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

US Patent Number : 11925661

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212832

Patent Use Code : U-4185

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2041-10-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

FRESENIUS KABI USA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

The Aesthetic Show

Not Confirmed

FRESENIUS KABI USA

The Aesthetic Show

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2041-10-12

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

US Patent Number : 11813291

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212832

Patent Use Code : U-4185

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2041-10-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

FRESENIUS KABI USA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

The Aesthetic Show

Not Confirmed

FRESENIUS KABI USA

The Aesthetic Show

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2041-10-12

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

US Patent Number : 11813291

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212832

Patent Use Code : U-4185

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2041-10-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!